相关实验视频

Updated: Sep 10, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

通过调节PI15抑制TGF-β/Smad路径,改善肺纤维化发展

Dong Xia¹, Xingyan Liu¹, Qiuting Yang¹

¹The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.

Journal of cellular and molecular medicine

|August 22, 2025

概括

通过抑制酶抑制剂15 (PI15) 和调节关键信号通路,Cinobufotalin (CB) 在治疗肺纤维化 (PF) 中具有前景. 这项研究确定CB为PF患者的潜在治疗候选药物.

科学领域:

肺部医学
药理学
分子生物学

背景情况:

肺纤维化 (PF) 是一种严重的间歇性肺病 (ILD),治疗选择有限.
一个小分子Cinobufotalin (CB) 已显示出抗癌性质.
转化生长因子β1 (TGF-β1) 信号驱动纤维化通过肌纤维细胞激活和上皮介质转化 (EMT).

研究的目的:

在肺纤维化 (PF) 治疗中研究青素 (CB) 的治疗潜力.
阐明CB抗纤维作用的分子机制.
确定用于PF治疗的新分子点.

主要方法:

用白素 (BLM) 诱导的PF小鼠模型.
在体外研究TGF-β1诱导的肌纤维细胞激活和EMT.
用于基因表达分析的比较RNA测序 (RNA-Seq).
对TGF-β/Smad信号通路的机制研究.

主要成果:

治疗CB减弱了BLM诱导的PF.
CB抑制了TGF-β1诱导的肌纤维细胞激活和EMT.
酶抑制剂15 (PI15) 被确定为PF中显著差异表达的基因.
通过抑制PI15和调节TGF-β/Smad通路,CB具有抗纤维作用.

结论:

在临床前模型中,Cinobufotalin (CB) 显示出显著的抗纤维作用.
通过抑制PI15和调节TGF-β/Smad信号通路而起作用.
这是一种有前途的肺纤维化疗法.

关键词:

一个EMT 没有.TGF-β/Smad路径其他类药物肺纤维化

更多相关视频

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...